Viking Therapeutics VKTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's additional paid-in capital?
- Viking Therapeutics (VKTX) reported additional paid-in capital of $1.51B in Q1 2026.
- How has Viking Therapeutics's additional paid-in capital changed year-over-year?
- Viking Therapeutics's additional paid-in capital increased by 9.3% year-over-year, from $1.38B to $1.51B.
- What is the long-term trend for Viking Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Viking Therapeutics's additional paid-in capital has grown at a 29.2% compound annual growth rate (CAGR), from $412.59M to $1.49B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.